UK markets close in 7 hours 4 minutes
  • FTSE 100

    7,467.26
    +27.52 (+0.37%)
     
  • FTSE 250

    20,058.37
    +6.89 (+0.03%)
     
  • AIM

    921.28
    +0.90 (+0.10%)
     
  • GBP/EUR

    1.1863
    +0.0012 (+0.10%)
     
  • GBP/USD

    1.2089
    +0.0018 (+0.15%)
     
  • BTC-GBP

    19,705.36
    +597.89 (+3.13%)
     
  • CMC Crypto 200

    552.81
    +17.59 (+3.29%)
     
  • S&P 500

    4,145.19
    -6.75 (-0.16%)
     
  • DOW

    32,803.47
    +76.67 (+0.23%)
     
  • CRUDE OIL

    88.57
    -0.44 (-0.49%)
     
  • GOLD FUTURES

    1,791.40
    +0.20 (+0.01%)
     
  • NIKKEI 225

    28,249.24
    +73.37 (+0.26%)
     
  • HANG SENG

    20,045.77
    -156.17 (-0.77%)
     
  • DAX

    13,646.96
    +73.03 (+0.54%)
     
  • CAC 40

    6,513.92
    +41.57 (+0.64%)
     

Illumina loses challenge against EU antitrust probe into Grail deal

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
FILE PHOTO: The offices of gene sequencing company Illumina Inc are shown in San Diego, California
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

By Foo Yun Chee

LUXEMBOURG (Reuters) -U.S. life sciences company Illumina on Wednesday lost its challenge against European Union scrutiny of its $8 billion cash-and-stock takeover of Grail, as a top European court agreed the EU antitrust watchdog had the right to do so.

The case is important for EU antitrust chief Margrethe Vestager who wants to expand the European Commission's power to examine acquisitions of startups by big companies that could seek to shut nascent rivals, particularly in tech and pharmaceuticals deals.

Her critics see it as a power grab that has triggered alarm bells at some national competition agencies.

Illumina said it would appeal the ruling to the Court of Justice of the European Union, Europe's highest.

"The Commission has the competence to examine that concentration which did not have a European dimension or fall within the scope of the national merger control rules of member states of the European Union or states party to the agreement on the European Economic Area," the General Court said.

Judges rejected Illumina's complaint that the EU competition enforcer's action had up-ended legal certainty and legitimate expectations in the merger process.

They said the company had failed to show that it "received precise, unconditional and consistent assurances, originating from authorised, reliable sources, such as to lead him or her to entertain well-founded expectations".

The Commission said it took up the Illumina case at the request of Belgium, France, Greece, Iceland, the Netherlands and Norway even though the deal did not require approval from these countries because Grail had no activities in Europe.

Illumina announced the deal in September 2020 that would give it access to Grail's flagship Galleri blood test used to diagnose cancers at early stages when the disease is easier to treat.

It completed the acquisition in August 2021 without waiting for EU clearance and was subsequently told to keep Grail separate and to have independent managers run the company until regulators finalised their investigation in another procedure.

The case is T-227/21 Illumina v Commission.

(Additional reporting by Marine Strauss in Brussels; Editing by Edmund Blair)

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting